Red
Brand Name(s):Orencia
Indication:Rheumatoid arthritis, Juvenile idiopathic arthritis & Active psoriatic arthritis in adults
Rationale:1,2,8
Considered:Apr-09
Review Date:Jul-22
Comments:
NICE TA 375
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed.
Full information can be found at:http://www.nice.org.uk/guidance/ta375/resources/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed-82602790920133
January 2016 NICE technology appraisal guidance [TA373]